Non-Muscle Invasive Bladder Cancer

This is a type of bladder cancer that starts in the thin lining of the bladder. The cancer cells stay in the lining and have not grown into the bladder muscle. It's a common type of bladder cancer and is often treatable.

Condition

What people with Non-Muscle Invasive Bladder Cancer report

Every report comes from a Lived member, sent anonymously.

Have you had Transurethral Resection of Bladder for Non-Muscle Invasive Bladder Cancer?

NameHow it went

About Non-Muscle Invasive Bladder Cancer

What It Is

Non-muscle invasive bladder cancer (NMIBC) is bladder cancer that is still confined to the inner layers of the bladder wall and has not grown into the thick muscle layer beneath them. Bladder cancer starts in the lining of the bladder, and most people with bladder cancer have this non-muscle invasive form when they are first diagnosed. It used to be called superficial bladder cancer. The most common sign is blood in the urine. It may look rusty to bright red, it may appear once and then not again for a while, or it may be found only on a urine test. Some people instead notice burning, needing to urinate often, or feeling an urge to go when the bladder is not full, symptoms that are more often caused by infections or stones. NMIBC includes three kinds of tumor. Papillary tumors (stage 0a, also written Ta) grow like thin fronds from the lining into the hollow of the bladder. Carcinoma in situ (stage 0is, or CIS) is flat, stays within the lining and is always high grade. Stage I (T1) tumors have grown into the connective tissue just under the lining but not into the muscle. Doctors also grade the cells: low-grade cancers look more like normal cells and tend to grow slowly, while high-grade cancers grow faster and are more likely to become invasive. The line between non-muscle invasive and muscle-invasive cancer matters because it changes almost everything about treatment. NMIBC can often be cured while keeping the bladder, but it has a strong tendency to come back, so living with it usually means repeated bladder checks over years.

Causes & Risk Factors

Bladder cancer develops when cells in the bladder lining build up DNA changes that let them grow out of control. Tobacco, especially cigarette smoking, is the major risk factor that people can change. Cancer-causing chemicals in smoke are absorbed into the blood, filtered by the kidneys and collected in the urine, so the bladder lining is exposed to them while urine is stored. Risk also rises with age and is higher in men. Other recognized risk factors include a family history of bladder cancer, workplace exposure to certain paints, dyes, metals or petroleum products, past radiation to the pelvis, past treatment with the chemotherapy drugs cyclophosphamide or ifosfamide, well water with high arsenic levels, long-term use of urinary catheters, and schistosomiasis, a parasitic bladder infection that is rare in the United States. These factors raise the chance of the DNA damage that leads to cancer; many people with them never develop bladder cancer, and some people with none do.

How It's Diagnosed

Evaluation usually begins with a urine sample checked for blood, infection or abnormal cells, along with questions about symptoms, smoking and work exposures. The key test is cystoscopy: a thin, lighted tube passed through the urethra (the tube that carries urine out of the body) lets the doctor look directly at the bladder lining. Imaging such as a computed tomography (CT) urogram, a CT scan with contrast dye timed to show the kidneys, the ureters and the bladder, checks the rest of the urinary tract, where similar tumors can also form. If a tumor is seen, the diagnosis is confirmed by transurethral resection of bladder tumor (TURBT). Under general or regional anesthesia, the surgeon passes an instrument through the urethra, removes the visible tumor along with some of the deeper bladder wall, and sends the tissue to a pathologist, who reports how deep the cancer has grown and its grade. Because muscle invasion can only be ruled out when muscle has been sampled, a repeat TURBT a few weeks later is common when the first sample did not include muscle, did not remove enough tumor, or showed high-risk features. Doctors then combine the stage, grade, size and number of tumors, the presence of carcinoma in situ and any earlier recurrence into a risk group: low, intermediate or high, with some cancers called very high risk. The risk group estimates how likely the cancer is to come back or to grow into the muscle, and it guides nearly every later decision.

Treatment Options

TURBT is both the diagnostic step and the first treatment. Most people go home the same day or the next day, and some bleeding and pain when urinating is common right afterward. Removing the visible tumor does not remove the tendency of the bladder lining to form new tumors, so what follows depends on the risk group. Intravesical therapy means placing a drug directly into the bladder through a thin tube called a catheter. The drug acts on the lining and has very little effect elsewhere in the body, which is why it suits cancer that has not grown deep into the wall. A single dose of chemotherapy, usually gemcitabine or mitomycin, is often given within a day of TURBT to lower the chance of the cancer coming back. For low-risk tumors this may be all the treatment needed, followed by regular cystoscopy. For intermediate-risk cancer, a course of weekly treatments for about six weeks is usual, using chemotherapy or BCG (bacillus Calmette-Guérin), sometimes continued as maintenance for about a year. BCG is a weakened bacterium related to the one that causes tuberculosis; placed in the bladder, it switches on immune cells that attack the cancer. It is the main treatment for high-risk NMIBC, including carcinoma in situ, given weekly for six weeks and then as maintenance for up to three years. Flu-like symptoms, burning in the bladder, frequent urination and some blood in the urine are common for two to three days after a dose. BCG is usually not recommended for people with weakened immune systems, because serious BCG infection, though rare, is more likely. When high-risk cancer does not respond to BCG, or has very high-risk features, removing the bladder (radical cystectomy) gives the most definitive control. It is major surgery, and the surgeon creates a new way for urine to leave the body, called a urinary diversion. For people who cannot have or do not want cystectomy, options include more intravesical chemotherapy, newer treatments placed in the bladder (immune-activating and gene therapy medicines, or a small device that slowly releases gemcitabine), and pembrolizumab (Keytruda), an immunotherapy given through a vein that is approved for BCG-unresponsive cancer with carcinoma in situ. Clinical trials are a reasonable option to ask about at this stage.

What to Expect

For most people, NMIBC is managed over years rather than with a single treatment. Because it often comes back even after a complete TURBT, cystoscopy is usually repeated about every three months for the first couple of years and then less often if no new tumors are found. Urine tests and imaging of the rest of the urinary tract may be added. Urine marker tests can help, but none has replaced cystoscopy. The outlook depends heavily on the risk group. Low-risk cancers can almost always be cured. New tumors that appear during follow-up are usually small and superficial and can be treated with another TURBT, or sometimes by burning small low-grade tumors during an office cystoscopy. Intermediate- and high-risk cancers are more likely to return and can come back as cancer growing into the muscle or beyond, which is why their treatment is more intensive and their follow-up closer. If TURBT has to be repeated many times, the bladder can become scarred and hold less urine, leading to frequent urination or leakage. A course of bladder treatments means regular clinic visits for weeks to years, and the irritation after each dose comes and goes. Many people find it hard not to worry about the next check, and a written survivorship plan that lays out the schedule of tests can make the process more predictable. Not smoking matters: people who keep smoking appear more likely to have the cancer come back, although it is not yet proven that quitting lowers that risk, and quitting has many other health benefits.

When to Seek Help

See a clinician about any blood in the urine, even if it happened once and caused no pain, and about frequent, painful or urgent urination without a clear cause. After a diagnosis, keep every scheduled cystoscopy, and tell the care team about new blood in the urine or new urinary symptoms between visits rather than waiting for the next appointment. During BCG treatment, a few days of flu-like symptoms are expected. Call the care team right away for a high fever that does not go away, which can be a sign of a serious BCG infection.

Questions to Ask Your Doctor

  1. 1.What are the stage, grade and risk group of my cancer, and did the tissue sample include bladder muscle?
  2. 2.Do I need a repeat TURBT or treatment placed in the bladder, and what does each step add for someone in my risk group?
  3. 3.What schedule of cystoscopy and imaging will I need, and how will it change if things stay clear?
  4. 4.If BCG is recommended, what side effects should I expect, and what is the plan if it is unavailable or does not work?
  5. 5.At what point would removing the bladder be worth discussing, and what would life with a urinary diversion involve?

Last reviewed • Oct 2026

Educational content, not medical advice.